On January 18th, The AMR Industry Alliance launched its first report that shows the commitment of the life sciences industry to tackle the public health threat of antimicrobial resistance (AMR).
The Alliance brings together over 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations from 20 countries.
The data and case studies collected in the Alliance report provide unique insights into the practical steps members are taking to respond to AMR in the areas of research and science, access, appropriate use, and the environment.
The Test Target Treat™ initiative is featured as a case study on the commitment by industry to promote appropriate use of antimicrobials.
AMR has the potential to turn back the clock on modern medicine. In response to this public health threat and its social and economic consequences, the United Nations in 2016 called for concerted action from governments and various sectors to address the implications of AMR. The AMR Industry Alliance is the life sciences industry’s response to this call for action.
“This first report is ground-breaking for several reasons,” explains Thomas Cueni, chair of the Alliance. “It is unique in that the companies have committed to walk the talk together and report on their progress. It is the first industry-wide grouping of this scale that has been set up to respond to the AMR emergency.”
The report measure progress in four areas:
- Research and science
- Appropriate use
- Manufacturing and the environment